Mattia Galli/LinkedIn
Nov 2, 2025, 05:36
Mattia Galli on Use of Genetic Testing to Guide the Choice of Antiplatelet Drugs
Mattia Galli, Assistant Professor at Sapienza University of Rome, Associate Editor of European Heart Journal, shared on LinkedIn:
”Growing interest in Rome in the use of genetic testing to guide the choice of antiplatelet drugs.
Is the time finally ripe for cardiology to move towards precision drug therapy?
A wonderful meeting and stimulating discussion with colleagues from one of Rome’s most important hospitals, in a session moderated by some of the “teachers” I had the pleasure of meeting during my specialization course.
Francesco Burzotta, Gaetano Antonio Lanza.”
Stay updated with Hemostasis Today.
-
Apr 8, 2026, 07:32Giulia Simini: Acquired von Willebrand Syndrome and Coagulation Abnormalities in MPN-Associated Thrombocytosis
-
Apr 8, 2026, 07:14Julian Kyoung-Ryul Chun: Join the Discussion at EHRA 2026
-
Apr 8, 2026, 06:41Stephanie Diez de Sollano: Why Ehlers-Danlos Syndrome Deserves More Attention
-
Apr 7, 2026, 19:17Anand Padmanabhan: Persistence and Pathogenicity of Platelet Factor 4 Antibodies in VITT
-
Apr 7, 2026, 19:07Clara Meijs: Great Time Presenting Our Endometriosis Project at the AHA EPI Lifestyle Conference
-
Apr 7, 2026, 18:18Vivek Das: How Obesity, Type 2 Diabetes, and Dyslipidaemia Interact Across Multiple Cardiovascular Conditions
-
Apr 7, 2026, 17:44Augustina Isioma Ikusemoro: Quality Indicators for Red Blood Cells in Transfusion Medicine
-
Apr 7, 2026, 17:35Nikola Grubor: In Situ Pulmonary Arterial Thrombosis Mimicking CTEPH in Eisenmenger
-
Apr 7, 2026, 17:34Pooja Choradia: vWF Breakdown in Aortic Stenosis – Anaemia and Pulmonary Relevance